Which has preferable earnings & valuation, ENGN or KMDA?

Kamada has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enGene N/A N/A -$117.30M -$1.13 N/A Kamada $180.46M 2.82 $20.20M $0.38 23.29

Is ENGN or KMDA more profitable?

Kamada has a net margin of 11.60% compared to enGene's net margin of 0.00%. Kamada's return on equity of 8.37% beat enGene's return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -27.97% -22.65% Kamada 11.60% 8.37% 5.85%

Does the media refer more to ENGN or KMDA?

In the previous week, enGene had 10 more articles in the media than Kamada. MarketBeat recorded 17 mentions for enGene and 7 mentions for Kamada. Kamada's average media sentiment score of 0.56 beat enGene's score of 0.19 indicating that Kamada is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 2 Very Positive mention(s) 2 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kamada 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, ENTX or ENGN?

Entera Bio has higher revenue and earnings than enGene. Entera Bio is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Entera Bio $40K 12,863.42 -$11.44M -$0.35 N/A enGene N/A N/A -$117.30M -$1.13 N/A

Is ENTX or ENGN more profitable?

enGene's return on equity of -27.97% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Entera Bio N/A -147.19% -103.22% enGene N/A -27.97% -22.65%

Does the media favor ENTX or ENGN?

In the previous week, enGene had 9 more articles in the media than Entera Bio. MarketBeat recorded 17 mentions for enGene and 8 mentions for Entera Bio. Entera Bio's average media sentiment score of 0.39 beat enGene's score of 0.19 indicating that Entera Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entera Bio 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral enGene 2 Very Positive mention(s) 2 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ENGN or AVTE?

enGene currently has a consensus target price of $11.05, suggesting a potential upside of 478.30%. Given enGene's stronger consensus rating and higher possible upside, equities analysts plainly believe enGene is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enGene 2 Sell rating(s) 8 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.14 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, ENGN or AVTE?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enGene N/A N/A -$117.30M -$1.13 N/A Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A

Is ENGN or AVTE more profitable?

enGene's return on equity of -27.97% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -27.97% -22.65% Aerovate Therapeutics N/A -90.19% -77.47%

Does the media favor PBYI or ENGN?

In the previous week, enGene had 8 more articles in the media than Puma Biotechnology. MarketBeat recorded 17 mentions for enGene and 9 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.48 beat enGene's score of 0.19 indicating that Puma Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral enGene 2 Very Positive mention(s) 2 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, MPLT or ENGN?

enGene is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maplight Therapeutics N/A N/A -$161.15M -$42.31 N/A enGene N/A N/A -$117.30M -$1.13 N/A

Is MPLT or ENGN more profitable?

enGene's return on equity of -27.97% beat Maplight Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Maplight Therapeutics N/A -98.60% -60.33% enGene N/A -27.97% -22.65%

Does the media refer more to MPLT or ENGN?

In the previous week, enGene had 15 more articles in the media than Maplight Therapeutics. MarketBeat recorded 17 mentions for enGene and 2 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.51 beat enGene's score of 0.19 indicating that Maplight Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive enGene 2 Very Positive mention(s) 2 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

enGene (ENGN) Competitors

$1.91 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.91 0.00 (-0.21%)

As of 09/18/2026 07:50 PM Eastern

Compare

ENGN vs. KMDA, ENTX, AVTE, PBYI, and MPLT

Should you buy enGene stock or one of its competitors? enGene's main competitors and comparable companies include Kamada (KMDA), Entera Bio (ENTX), Aerovate Therapeutics (AVTE), Puma Biotechnology (PBYI), and Maplight Therapeutics (MPLT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does enGene compare to Kamada?

enGene (NASDAQ:ENGN) and Kamada (NASDAQ:KMDA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

enGene has a beta of -0.28, indicating that its share price is 128% less volatile than the broader market. Comparatively, Kamada has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

Kamada has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$1.13	N/A
Kamada	$180.46M	2.82	$20.20M	$0.38	23.29

64.2% of enGene shares are held by institutional investors. Comparatively, 20.4% of Kamada shares are held by institutional investors. 10.5% of enGene shares are held by insiders. Comparatively, 36.1% of Kamada shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Kamada has a net margin of 11.60% compared to enGene's net margin of 0.00%. Kamada's return on equity of 8.37% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-27.97%	-22.65%
Kamada	11.60%	8.37%	5.85%

In the previous week, enGene had 10 more articles in the media than Kamada. MarketBeat recorded 17 mentions for enGene and 7 mentions for Kamada. Kamada's average media sentiment score of 0.56 beat enGene's score of 0.19 indicating that Kamada is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	2 Very Positive mention(s)	2 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kamada	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

enGene currently has a consensus target price of $11.05, suggesting a potential upside of 478.30%. Kamada has a consensus target price of $13.50, suggesting a potential upside of 52.54%. Given enGene's higher probable upside, research analysts clearly believe enGene is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14
Kamada	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Kamada beats enGene on 11 of the 14 factors compared between the two stocks.

How does enGene compare to Entera Bio?

Entera Bio (NASDAQ:ENTX) and enGene (NASDAQ:ENGN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Entera Bio currently has a consensus price target of $9.00, suggesting a potential upside of 204.05%. enGene has a consensus price target of $11.05, suggesting a potential upside of 478.30%. Given enGene's higher probable upside, analysts clearly believe enGene is more favorable than Entera Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14

14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 64.2% of enGene shares are owned by institutional investors. 10.6% of Entera Bio shares are owned by company insiders. Comparatively, 10.5% of enGene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Entera Bio has higher revenue and earnings than enGene. Entera Bio is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	$40K	12,863.42	-$11.44M	-$0.35	N/A
enGene	N/A	N/A	-$117.30M	-$1.13	N/A

enGene's return on equity of -27.97% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-147.19%	-103.22%
enGene	N/A	-27.97%	-22.65%

In the previous week, enGene had 9 more articles in the media than Entera Bio. MarketBeat recorded 17 mentions for enGene and 8 mentions for Entera Bio. Entera Bio's average media sentiment score of 0.39 beat enGene's score of 0.19 indicating that Entera Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entera Bio	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
enGene	2 Very Positive mention(s)	2 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Entera Bio has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market. Comparatively, enGene has a beta of -0.28, suggesting that its stock price is 128% less volatile than the broader market.

Summary

Entera Bio and enGene tied by winning 7 of the 14 factors compared between the two stocks.

How does enGene compare to Aerovate Therapeutics?

enGene (NASDAQ:ENGN) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

enGene has a beta of -0.28, suggesting that its stock price is 128% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

enGene's return on equity of -27.97% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-27.97%	-22.65%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

In the previous week, enGene had 17 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 17 mentions for enGene and 0 mentions for Aerovate Therapeutics. enGene's average media sentiment score of 0.19 beat Aerovate Therapeutics' score of 0.00 indicating that enGene is being referred to more favorably in the media.

Company	Overall Sentiment
enGene	Neutral
Aerovate Therapeutics	Neutral

enGene currently has a consensus target price of $11.05, suggesting a potential upside of 478.30%. Given enGene's stronger consensus rating and higher possible upside, equities analysts plainly believe enGene is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$1.13	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

64.2% of enGene shares are held by institutional investors. 10.5% of enGene shares are held by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

enGene beats Aerovate Therapeutics on 10 of the 13 factors compared between the two stocks.

How does enGene compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and enGene (NASDAQ:ENGN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Puma Biotechnology has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, enGene has a beta of -0.28, meaning that its share price is 128% less volatile than the broader market.

Puma Biotechnology has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	2.17	$31.11M	$0.52	18.46
enGene	N/A	N/A	-$117.30M	-$1.13	N/A

61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 22.2% of Puma Biotechnology shares are held by insiders. Comparatively, 10.5% of enGene shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Puma Biotechnology currently has a consensus target price of $6.00, suggesting a potential downside of 37.50%. enGene has a consensus target price of $11.05, suggesting a potential upside of 478.30%. Given enGene's stronger consensus rating and higher probable upside, analysts plainly believe enGene is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14

Puma Biotechnology has a net margin of 11.50% compared to enGene's net margin of 0.00%. Puma Biotechnology's return on equity of 20.76% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	11.50%	20.76%	13.22%
enGene	N/A	-27.97%	-22.65%

In the previous week, enGene had 8 more articles in the media than Puma Biotechnology. MarketBeat recorded 17 mentions for enGene and 9 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.48 beat enGene's score of 0.19 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
enGene	2 Very Positive mention(s)	2 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Puma Biotechnology beats enGene on 10 of the 15 factors compared between the two stocks.

How does enGene compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and enGene (NASDAQ:ENGN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

64.2% of enGene shares are owned by institutional investors. 3.8% of Maplight Therapeutics shares are owned by company insiders. Comparatively, 10.5% of enGene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, enGene had 15 more articles in the media than Maplight Therapeutics. MarketBeat recorded 17 mentions for enGene and 2 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.51 beat enGene's score of 0.19 indicating that Maplight Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
enGene	2 Very Positive mention(s)	2 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

enGene's return on equity of -27.97% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	-98.60%	-60.33%
enGene	N/A	-27.97%	-22.65%

enGene is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$42.31	N/A
enGene	N/A	N/A	-$117.30M	-$1.13	N/A

Maplight Therapeutics presently has a consensus target price of $29.50, suggesting a potential upside of 170.15%. enGene has a consensus target price of $11.05, suggesting a potential upside of 478.30%. Given enGene's higher possible upside, analysts plainly believe enGene is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.94
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

enGene beats Maplight Therapeutics on 8 of the 13 factors compared between the two stocks.

Get enGene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENGN vs. The Competition

Export

Metric	enGene	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$127.94M	$3.89B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	-1.69	14.23	275.49	25.40
Price / Sales	N/A	1,419.61	646.01	89.45
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	0.56	15.45	10.46	6.33
Net Income	-$117.30M	-$22.86M	$3.49B	$358.33M
7 Day Performance	6.11%	-1.21%	0.59%	1.12%
1 Month Performance	7.91%	-3.29%	-1.74%	-2.39%
1 Year Performance	-71.99%	37.74%	18.13%	5.35%

enGene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENGN enGene	3.9335 of 5 stars	$1.91 flat	$11.05 +478.3%	-72.0%	$127.94M	N/A	N/A	82
KMDA Kamada	4.9713 of 5 stars	$8.85 +2.0%	$13.50 +52.6%	+28.1%	$508.68M	$180.46M	23.28	462	News Coverage Analyst Forecast
ENTX Entera Bio	2.8527 of 5 stars	$2.90 -4.2%	$9.00 +210.1%	+64.4%	$504.63M	$40K	N/A	21	News Coverage Analyst Forecast Gap Up
AVTE Aerovate Therapeutics	N/A	$17.14 +2.9%	N/A	+119.7%	$496.80M	N/A	N/A	20	High Trading Volume
PBYI Puma Biotechnology	1.0885 of 5 stars	$9.58 +0.6%	$6.00 -37.3%	+117.2%	$494.26M	$228.40M	18.41	179	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENGN) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

enGene (ENGN) Competitors

ENGN vs. KMDA, ENTX, AVTE, PBYI, and MPLT

How does enGene compare to Kamada?

Summary

How does enGene compare to Entera Bio?

Summary

How does enGene compare to Aerovate Therapeutics?

Summary

How does enGene compare to Puma Biotechnology?

Summary

How does enGene compare to Maplight Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENGN vs. The Competition

enGene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

enGene (ENGN) Competitors

ENGN vs. KMDA, ENTX, AVTE, PBYI, and MPLT

How does enGene compare to Kamada?

Which has more risk and volatility, ENGN or KMDA?

Which has preferable earnings & valuation, ENGN or KMDA?

Do institutionals and insiders hold more shares of ENGN or KMDA?

Is ENGN or KMDA more profitable?

Does the media refer more to ENGN or KMDA?

Do analysts prefer ENGN or KMDA?

Summary

How does enGene compare to Entera Bio?

Do analysts recommend ENTX or ENGN?

Do institutionals & insiders have more ownership in ENTX or ENGN?

Which has preferable earnings and valuation, ENTX or ENGN?

Is ENTX or ENGN more profitable?

Does the media favor ENTX or ENGN?

Which has more volatility & risk, ENTX or ENGN?

Summary

How does enGene compare to Aerovate Therapeutics?

Which has more volatility & risk, ENGN or AVTE?

Is ENGN or AVTE more profitable?

Does the media refer more to ENGN or AVTE?

Do analysts prefer ENGN or AVTE?

Which has better earnings and valuation, ENGN or AVTE?

Do institutionals and insiders hold more shares of ENGN or AVTE?

Summary

How does enGene compare to Puma Biotechnology?

Which has more risk and volatility, PBYI or ENGN?

Which has stronger earnings & valuation, PBYI or ENGN?

Do insiders and institutionals believe in PBYI or ENGN?

Do analysts prefer PBYI or ENGN?

Is PBYI or ENGN more profitable?

Does the media favor PBYI or ENGN?

Summary

How does enGene compare to Maplight Therapeutics?

Do insiders & institutionals hold more shares of MPLT or ENGN?

Does the media refer more to MPLT or ENGN?

Is MPLT or ENGN more profitable?

Which has stronger valuation and earnings, MPLT or ENGN?

Do analysts recommend MPLT or ENGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENGN vs. The Competition

enGene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools